Optimal Timing of Feeding After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding: A Randomized, Noninferiority Trial (CRIS KCT0001019)

This study was a randomized, single center, noninferiority trial. Consecutive patients with peptic ulcer bleeding were randomized to resume feeding either 24 or 48 hours after successful endoscopic hemostasis. Recurrent bleeding rates at 7 days were 7.9% in the 24-hour group and 4.0% in 48-hour groups. The transfusion requirement and the length of hospital stay were similar between the 2 groups. Our results do not allow a recommendation of refeeding at 24 hours, rather than later, in this popula

Systematic review and meta-analysis: monopolar hemostatic forceps with soft coagulation in the treatment of peptic ulcer bleeding

Monopolar hemostatic forceps with soft coagulation (MHFSC) have been compared with other modalities for peptic ulcer bleeding treatment. MHFSC was superior to othermodalities in achieving initial hemostasis and prevention of rebleeding. Procedure times were shorter with MHF SC and length of hospital stay was shorter with the forceps, but rates of adverse events were similar to those of other treatments.

Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding

It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. We randomly assigned patients with high risk of further bleeding or death to either an urgent endoscope or an early endoscope. The primary end point was death from any cause within 30 days after randomization. The 30-day mortality was 8.9% (23 of 258 patients) in the urgent-endoscopy group and 6.6% in the early-endoscope group.

Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review

Helicobacter pylori is a spiral-shaped gram-negative bacteria associated with peptic ulcer, gastritis and gastric cancer. H.pylori-pooled overall prevalence rate of antibiotic resistance was found to be 4.55% to amoxicillin, 27.22% to clarithromycin, 39.66% to metronidazole, and 22.48% (95% CI: 21.24-23.76%) to levofloxacin.

Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer

Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. In a phase 3, double-blind, active control, multicentre study, 306 ulcer patients were randomised to one of three treatment groups. The cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazAn 50 mg, 95.0% (94/99) for tegocrazan 100 mg and 95.7% (89/93) for lansobrazole 30 mg.

Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials

Study looked for randomized controlled trials that examined the efficacy and safety of gastrointestinal bleeding prophylaxis with PPIs, H2RAs, or sucralfate vs. one another or placebo. Findings: Both PPIs and H 2RAs probably reduce clinically important gastrointestinal bleeding. The magnitude of reduction is probably greater in PPIs than H2 RAs, and the difference may be important in higher, but not lower bleeding risk patients. The possibility that PPIs may slightly increase mortality can't be

Laryngopharyngeal reflux, gastroesophageal reflux and dental disorders: A systematic review

Study results supported a higher prevalence of dental erosion and caries in reflux patients compared with healthy individuals. The involvement of reflux in the development of dental disorders is not formally demonstrated. Future investigations should consider pharyngeal acid and nonacid reflux episodes as well as their potential impact on oral microbiota. There is an important heterogeneous between studies about diagnostic methods and clinical outcome evaluation.

Statins and risk of peptic ulcer disease: A systematic review and meta-analysis

Peptic ulcer disease (PUD) is one of the most common gastrointestinal disorders worldwide. Studies have suggested the protective effect of statins against the development of PUD. This systematic review and meta-analysis was conducted with the aim of summarising all available data. The results did not reach statistical significance.

Departments

Recent Posts